Ctl responses of high functional avidity and broad variant cross-reactivity are associated with hiv control

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Mothe, Beatriz ^a,b   Llano, Anuska ^a   Ibarrondo, Javier ^a,k   Zamarreño, Jennifer ^a   Schiaulini, Mattia ^a,b   Miranda, Cristina ^a   Ruiz Riol, Marta ^a   Berger, Christoph T ^c   Herrero, M José ^a   Palou, Eduard ^a   Plana, Montse ^d   Rolland, Morgane ^e,l   Khatri, Ashok ^c   Heckerman, David ^f   Pereyra, Florencia ^c   Walker, Bruce D ^c,g   Weiner, David ^h   Paredes, Roger ^a   Clotet, Bonaventura ^a   Felber, Barbara K ⁱ   Pavlakis, George N ⁱ   Mullins, James I ^e   Brander, Christian ^a,j   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MICROSOFT RESEARCH   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l Military HIV Research Program   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG P24; GAG PROTEIN; HLA ANTIGEN CLASS 1; UNCLASSIFIED DRUG; T LYMPHOCYTE RECEPTOR;

ADULT; ALLELE; AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; ANTIGENIC VARIATION; ARTICLE; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; CROSS-SECTIONAL STUDY; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; LYMPHOCYTE FUNCTION; MALE; NUCLEOTIDE SEQUENCE; CASE CONTROL STUDY; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AMINO ACID SEQUENCE; CASE-CONTROL STUDIES; CROSS REACTIONS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; YOUNG ADULT;

EID: 84855396595     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029717     Document Type: Article

References (42)

1. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53.
2. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, et al. (2004) Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol 78: 3233-3243.
3. Mothe B, Ibarrondo J, Llano A, Brander C, (2009) Virological, immune and host genetics markers in the control of HIV infection. Dis Markers 27: 105-120.
4. Zuñiga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, et al. (2006) Relative dominance of Gag p24 specific CTL is associated with HIV control. J Virology 80: 3122-3125.
5. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, et al. (2007) Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 178: 2746-2754.
6. Schneidewind A, Brockman MA, Sidney J, Wang YE, Chen H, et al. (2008) Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J Virol 82: 5594-5605.
7. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, et al. (2011) High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated with Relative HIV Control. J Virol 85: 9334-9345.
8. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, et al. (2011) Protective HIV-specific CD8(+) T cells evade T(reg) cell suppression. Nat Med 17: 989-995.
9. Turnbull EL, Lopes AR, Jones NA, Cornforth D, Newton P, et al. (2006) HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J Immunol 176: 6130-6146.
10. Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, et al. (2003) Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 275: 19-29.
11. Dubey S, Clair J, Fu TM, Guan L, Long R, et al. (2007) Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 45: 20-27.
12. Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, et al. (2010) Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol 84: 4461-4468.
13. Rolland M, Nickle DC, Mullins JI, (2007) HIV-1 Group M Conserved Elements Vaccine. PLOS Pathogen 3: e157.
14. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, et al. (2004) Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 78: 2187-2200.
15. Frahm N, Kaufmann DE, Yusim K, Muldoon M, Kesmir C, et al. (2007) Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J Immunol 179: 6638-6650.
16. Dzutsev AH, Belyakov IM, Isakov DV, Margulies DH, Berzofsky JA, (2007) Avidity of CD8 T cells sharpens immunodominance. Int Immunol 19: 497-507.
17. Yerly D, Heckerman D, Allen TM, Chisholm JV 3rd, Faircloth K, et al. (2008) Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol 82: 3147-3153.
18. Prado JG, Molina JC, Blanco-Heredia J, Brander C, (2011) Immune Correlates of HIV Control. Curr Med Chem.
19. Fomsgaard A, Karlsson I, Gram G, Schou C, Tang S, et al. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine.
20. Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the step study. PLoS One 6: e20479.
21. Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M, et al. (2008) Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol 82: 9216-9227.
22. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, et al. (2001) Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193: 181-194.
23. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, et al. (2001) Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412: 334-338.
24. Pereyra F, Heckerman D, Rothchild A, Block B, Baker B, et al. (2008) Epitope specific CD8+ T-cell responses predict spontaneous HIV virus replication. AIDS Vaccine Meeting. Cape Town, South Africa.
25. Frahm N, Yusim K, Adams S, Sidney J, Hraber P, et al. (2007) Extensive HLA class I allele promiscuity among viral cytotoxic T lymphocyte (CTL) epitopes. Europ J Immunol 37: 2419-2433.
26. Llano A, Frahm N, Brander C, (2009) How to Optimally Define Optimal Cytotoxic T Lymphocyte Epitopes in HIV Infection? In: B. Korber CB, Walker B, Koup R, Moore J, Haynes B, Meyers G, editors. HIV Molecular immunology database Los Alamos, NM, USA Los Alamos National Laboratory: Theoretical Biology and Biophysics.
27. Horton H, Frank I, Baydo R, Jalbert E, Penn J, et al. (2006) Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 177: 7406-7415.
28. Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, et al. (2007) Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol 81: 4199-4214.
29. Betts MR, Price DA, Brenchley JM, Lore K, Guenaga FJ, et al. (2004) The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol 172: 6407-6417.
30. Alexander-Miller MA, Leggatt GR, Berzofsky JA, (1996) Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 93: 4102-4107.
31. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485.
32. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, et al. (2009) Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113: 6351-6360.
33. Bennett MS, Joseph A, Ng HL, Goldstein H, Yang OO, (2010) Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes. AIDS.
34. Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, et al. (2006) Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 176: 4094-4101.
35. Messaoudi I, Guevara Patino JA, Dyall R, LeMaoult J, N-Z J, (2002) Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 298: 1797-1780.
36. Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, et al. (2000) In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 74: 5769-5775.
37. Snyder JT, Alexander-Miller MA, Berzofskyl JA, Belyakov IM, (2003) Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res 1: 287-294.
38. Price DA, Brenchley JM, Ruff LE, Betts MR, Hill BJ, et al. (2005) Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med 202: 1349-1361.
39. Brander C, Goulder PJR, Luzuriaga K, Yang OO, Hartman K, et al. (1999) Persistent HIV-1 specific CTL clonal expansion despite high viral burden post in-utero HIV-1 infection. J Immunol 162: 4796-4800.
40. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, et al. (2000) Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 165: 1082-1092.
41. Oxenius A, Gunthard HF, Hirschel B, Fidler S, Weber JN, et al. (2001) Direct ex vivo analysis reveals distinct phenotypic patterns of HIV- specific CD8(+) T lymphocyte activation in response to therapeutic manipulation of virus load. Eur J Immunol 31: 1115-1121.
42. Weekes MP, Wills MR, Sissons JG, Carmichael AJ, (2006) Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy. Immunology 118: 25-38.